Evaluation of the anticancer activities of thioflavanone and thioflavone in human breast cancer cell lines

International Journal of Molecular Medicine

Volumn 29, Issue 2, 2012, Pages 252-256

  Choi, Eun Jeong ^a   Lee, Jae In ^a   Kim, Gun Hee ^a  

^a Duksung Women's University   (South Korea)

Author keywords

Anticancer; Cytotoxicity; Human breast cancer; Thioflavanone; Thioflavone

Indexed keywords

ANTINEOPLASTIC AGENT; FLAVONE DERIVATIVE; PROTEIN BAX; THIOFLAVANONE; THIOFLAVONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CARBON NUCLEAR MAGNETIC RESONANCE; CELL LINE; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL STRAIN MDA MB 231; CELL STRAIN MDA MB 453; CHEMICAL STRUCTURE; CHO CELL; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHO CELLS; CRICETINAE; FEMALE; FLAVANONES; FLAVONES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS;

EID: 84855173586     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.834     Document Type: Article

References (28)

1. Brown DM, Kelly GE and Husband AJ: Flavonoid compounds in maintenance of prostate health and prevention and treatment of cancer. Mol Biotechnol 30: 253-270, 2005. (Pubitemid 41272813)
2. Gates MA, Vitonis AF, Tworoger SS, Rosner B, Titus-Ernstoff L, Hankinson SE and Cramer DW: Flavonoid intake and ovarian cancer risk in a population-based case-control study. Int J Cancer 24: 1918-1925, 2009.
3. Peterson J, Lagiou P, Samoli E, Lagiou A, Katsouyanni K, La Vecchia C, Dwyer J and Trichopoulos D: Flavonoid intake and breast cancer risk: a case control study in Greece. Br J Cancer 89: 1255-1259, 2003. (Pubitemid 37363413)
4. Benavente-García O and Castillo J: Update on uses and properties of citrus flavonoids: new findings in anticancer, cardiovascular, and anti-inflammatory activity. J Agric Food Chem 56: 6185-6205, 2008.
5. Iwashina T: Flavonoid function and activity to plants and other organisms. Biol Sci Space 17: 24-44, 2003.
6. Pick A, Müller H, Mayer R, Haenisch B, Pajeva IK, Weigt M, Bonisch H, Muller CE and Wiese M: Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). Bioorg Med Chem 19: 2090-2102, 2011.
7. Wang HK, Xia Y, Yang ZY, Natschke SL and Lee KH: Recent advances in the discovery and development of flavonoids and their analogues as antitumor and anti-HIV agents. Adv Exp Med Biol 439: 191-225, 1998. (Pubitemid 28429018)
8. Zhang LB, Qiang L, Chen FH, Wu T, Rong JJ, Zhao Q, Zou MJ, Yang Z, You QD, Li ZY, Wu YL and Guo QL: DHF-18, a new synthetic flavonoid, induced a mitochondrial-mediated apoptosis of hepatocarcinoma cells in vivo and in vitro. Eur J Pharmacol 651: 33-40, 2011.
9. Chen HM, Chang FR, Hsieh YC, Cheng YJ, Hsieh KC, Tsai LM, Lin AS, Wu YC and Yuan SS: A novel synthetic protoapigenone analogue, WYC02-9, induces DNA damage and apoptosis in DU145 prostate cancer cells through generation of reactive oxygen species. Free Radic Biol Med 50: 1151-1162, 2011.
10. Liu YL, Ho DK, Cassady JM, Cook VM and Baird WM: Isolation of potential cancer chemopreventive agents from Eriodictyoncalifornicum. J Nat Prod 55: 357-363, 1992.
11. Min BS, Chung KS and Bae KH: Antitumor activity of 2(S)-5,2′, 5′-trihydroxy-7,8-dimethoxyflavanone and its analogues. Arch Pharm Res 20: 368-371, 1997. (Pubitemid 127697182)
12. Choi YJ, Lee MK, Lee YJ, Jeong YJ, Yoon Park JH, Sung Lim S and Kang YH: Inhibition of hydrogen peroxide-induced endothelial apoptosis by 2′,4′,7-trihydroxyflavanone, a flavonoid form. J Med Food 7: 408-416, 2004.
13. Ying M, Tu C, Ying H, Hu Y, He Q and Yang B: MSFTZ, a flavanone derivative, induces human hepatoma cell apoptosis via a reactive oxygen species- and caspase-dependent mitochondrial pathway. J Pharmacol Exp Ther 325: 758-765, 2008. (Pubitemid 351724320)
14. Lee JI and Jung MG: A new route for the synthesis of flavanones from 2-methoxybenzoic acids. Bull Korean Chem Soc 26: 2044.2046, 2005.
15. Lee JI, Jung MG and Jung HJ: A novel synthesis of flavanones from 2-hydroxybenzoic acids. Bull Korean Chem Soc 28: 859-862, 2007.
16. Lee JI: A new synthesis of thioflavanones from thiosalicylic acid. Bull Korean Chem Soc 29: 1263-1265, 2008.
17. Choi EJ, Lee JI and Kim GH: Anti-carcinogenic effect of a new analogue 4′-chloroflavanone from flavanone in human breast cancer cells. Int J Mol Med 25: 293-298, 2010.
18. Kim KS, Sack JS, Tokarski JS, Qian L, Chao ST, Leith L, Kelly YF, Misra RN, Hunt JT, Kimball SD, Humphreys WG, Wautlet BS, Mulheron JG and Webster KR: Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects. J Med Chem 43: 4126-4134, 2000.
19. Ahmed-Belkacem A, Pozza A, Muñoz-Martínez F, Bates SE, Castanys S, Gamarro F, Di Pietro A and Pérez-Victoria JM: Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. Cancer Res 65: 4852-4860, 2005. (Pubitemid 40740824)
20. Leopoldini M, Russo N and Toscano M: A comparative study of the antioxidant power of flavonoid catechin and its planar analogue. J Agric Food Chem 55: 7944-7949, 2007. (Pubitemid 47527021)
21. Hersey P and Zhang XD: Overcoming resistance of cancer cells to apoptosis. J Cell Physiol 196: 9-18, 2003. (Pubitemid 36676439)
22. Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H and Haga N: Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 94: 15-21, 2003. (Pubitemid 36575852)
23. Liebermann DA, Hoffman B and Steinman RA: Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene 11: 199-210, 1995.
24. Lepik D, Jaks V, Kadaja L, Värv S and Maimets T: Electroporation and carrier DNA cause p53 activation, cell cycle arrest, and apoptosis. Anal Biochem 318: 52-59, 2003. (Pubitemid 36637014)
25. McCurrach ME, Connor TM, Knudson CM, Korsmeyer SJ and Lowe SW: Bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci USA 94: 2345-2349, 1997. (Pubitemid 27136877)
26. Selvakumaran M, Lin HK, Miyashita T, Wang HG, Krajewski S, Reed JC, Hoffman B and Liebermann D: Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways. Oncogene 9: 1791-1798, 1994. (Pubitemid 24163410)
27. Llambi F and Green DR: Apoptosis and oncogenesis: give and take in the BCL-2 family. Curr Opin Genet Dev 21: 12-20, 2011.
28. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805, 1994. (Pubitemid 24163411)